Ardent Health (ARDT) Q3 2024 earnings summary

Executive summary

• Third quarter 2024 revenue grew 5.2% year-over-year to $1.45 billion, driven by higher patient volumes, improved case mix, and strategic execution.

• Adjusted EBITDA rose 15.3% to $98 million, with margin expansion of 50 basis points to 6.7%.

• Net income attributable to Ardent Health increased to $26.3 million ($0.19 per share), up from $20.8 million ($0.17 per share) in Q3 2023.

• Strategic initiatives in service line optimization, outpatient expansion, and technology (including AI) supported growth and efficiency.

• The company completed its IPO in July 2024, raising $208.7 million in net proceeds and enhancing capital flexibility.

Financial highlights

• Q3 2024 total revenue: $1.45 billion (+5.2% YoY); adjusted EBITDA: $98 million (+15.3% YoY); net income: $26.3 million (1.8% margin).

• Adjusted admissions grew 3.8% year-over-year; admissions up 6.4%; total surgeries up 0.3%.

• Net patient service revenue per adjusted admission increased 0.9% year-over-year to $16,312.

• Cash and available liquidity totaled $851 million at quarter-end; cash and equivalents were $563 million.

• Operating cash flow was $90 million in Q3 2024, up slightly year-over-year.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $5.8–$5.90 billion; adjusted EBITDA guidance increased to $425–$440 million.

• Net income guidance set at $156–$176 million, with EPS $1.18–$1.32, lowered due to delayed insurance proceeds from a cybersecurity incident.

• Adjusted admissions growth outlook raised to 4.5–5.0% for the year; net patient service revenue per adjusted admission growth forecast at 2.6–3.3%.

• Capital expenditures expected between $170–$185 million for 2024.

• Lease-adjusted net leverage ratio expected to approach 3.0x by year-end.